1 Title: MUC5AC genetic variation is associated with tuberculosis meningitis CSF

2 cytokine responses and mortality

- 3 Authors: Michelle C. Sabo¹, Nguyen T.T. Thuong^{2,3}, Xuling Chang⁴, Edwin Ardiansyah⁵,
- 4 Trinh T.B. Tram², Hoang T. Hai², Ho D.T. Nghia^{2,6}, Nguyen D. Bang^{6,7}, Sofiati Dian⁵, A.
- 5 Rizal Ganiem^{5,8}, Vinod Kumar⁵, Zheng Li⁹, Martin Hibberd¹⁰, Chiea Chuen Khor⁹, Guy E.
- 6 Thwaites^{2,3}, Dorothee Heemskerk^{2,3,11}, Arjan van Laarhoven⁵, Reinout van Crevel⁵, Sarah
- 7 J. Dunstan⁴, Javeed A. Shah^{1,12}
- 8 ¹Department of Internal Medicine, University of Washington, Seattle Washington, USA
- 9 ²Oxford University Clinical Research Unit, Ho Chi Minh, Vietnam
- ¹⁰ ³Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- ¹¹ ⁴Department of Infectious Diseases, University of Melbourne, at the Peter Doherty
- 12 Institute for Infection and Immunity, Melbourne, Australia
- 13 ⁵Radboud University Medical Center, Nijmegen, Netherlands
- ⁶Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
- ¹⁵ ⁷Pham Ngoc Thach Hospital, Ho Chi Minh, Vietnam
- ¹⁶ ⁸Department of Neurology, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung,
- 17 Indonesia
- ⁹Genome Institute of Singapore, Singapore
- ¹⁰London School of Tropical Medicine and Hygiene, London, United Kingdom
- 20 ¹¹Amsterdam University Medical Centre, Amsterdam, Netherlands
- 21 ¹²VA Puget Sound Healthcare System, Seattle, USA

Corresponding author: Michelle C. Sabo, 325 9th Avenue, Box 359909, Seattle WA 23 98104. Phone (440) 821-7962. Fax: (206) 543-4818. Email: sabo@uw.edu 24 25 Author Contributions: MCS, NTTT and JAS conceptualized and designed this analysis. MCS, NTTT, XC, SD, EA, AL, RC, VK, CCK, ZL, and JAS participated in analysis and 26 27 interpretation of data. Acquisition of data was performed by ARG, HDTN, NDB, GET, 28 DH, TTBT, HTH, CK, MH and SD. MCS and JAS drafted the original manuscript, with 29 XC and SD contributing important intellectual content during the drafting process. All 30 authors have approved the final version of this article prior to submission and agree to be 31 accountable for all aspects of the manuscript, including questions related to accuracy and 32 integrity of the work. Funding: This work was supported by the National Institute of Child Health and Human 33 34 Development [1K23HD100221 to MCS] and the National Institute of Allergy and Infectious 35 Diseases [R01 AI136921 to JAS and R01AI145781 to AvL, VK and RvC], both at the 36 National Institutes of Health, the University of Washington Center for AIDS Research [AI027757 to MCS], the Wellcome Trust Intermediate Fellowship in Public Health and 37 38 Tropical Medicine [206724/Z/17/Z to NTTT], Wellcome Trust Major Overseas Program 39 Funding [106680/B/14/Z to GT], and the National Health and Medical Research Council, 40 Australia (APP1056689 to SJD). 41 **Running title:** Tuberculosis meningitis and *MUC5AC*

Impact of Research: Mortality from tuberculosis meningitis remains unacceptably high.
This is the first study to show an association between risk of death from tuberculosis
meningitis and a polymorphism in *MUC5AC*, which is an important gel-forming mucin
expressed in lungs.

- **Subject category:** 11.4 Mycobacterial Disease: Host Defenses
- **Total word count**: 2,938

50 ABSTRACT

51 **Rationale:** Lung mucins are an understudied component of the mucosal immune 52 response and may influence tuberculosis pathogenesis and outcomes.

53 **Objectives:** To assess if variants in lung mucins *MUC5B* and *MUC5AC* are associated

54 with *Mycobacterium tuberculosis* immune responses, susceptibility, and outcomes.

55 **Methods:** We characterized four haplotype tagging single nucleotide polymorphisms 56 (SNPs) in *MUC5B* and *MUC5AC* for association with log₂ TNF concentrations in cerebral 57 spinal fluid (CSF) from TBM patients. SNPs associated with CSF TNF concentrations 58 were carried forward for analyses of pulmonary and meningeal TB susceptibility and TBM 59 mortality.

60 Measurements and Main Results: MUC5AC SNP rs28737416 T allele was associated 61 with lower CSF concentrations of TNF($p=1.8*10^{-8}$) and IFN γ ($p=2.3*10^{-6}$), and higher TBM, 62 but not pulmonary TB, susceptibility (OR 1.24, 95% confidence interval 1.03, 1.49; 63 p=0.021). Mortality from TBM was higher among participants with the rs28737416 T/T 64 and T/C genotype (35/119, 30.4%) versus the C/C genotype (11/89, 12.4%; log-rank 65 p=0.005) in a Vietnamese cohort (N=211). This finding was confirmed in an independent 66 Vietnamese validation cohort (N=87; 9/87, 19.1% vs 1/20, 2.5%; log-rank p=0.02) and an Indonesian validation cohort (N=468, 127/287, 44.3% vs 65/181, 35.9%, log-rank 67 68 p=0.06).

Conclusions: The *MUC5AC* rs28737416 T/T and T/C genotypes were associated with
higher susceptibility and mortality from TBM and lower CSF concentrations of TNF and
IFNγ compared to the C/C genotype, suggesting that *MUC5AC* contributes to immune
changes that influence TBM outcomes.

73 Abstract word count: 224

74 Keywords: Tuberculosis meningitis, MUC5AC, genetics, mucin

75 **INTRODUCTION**

Tuberculosis (TB) leads to over one million deaths annually (1). The clinical phenotype of TB disease is highly heterogenous, ranging from asymptomatic to severe disseminated infection and death (2). Tuberculosis meningitis (TBM) is the deadliest form of TB and leads to death or neurologic sequelae in over half of affected individuals (3). However, the factors that predispose individuals to symptomatic TB and TBM susceptibility and mortality are incompletely understood.

82 Lung mucins are complex glycoproteins on the surface of airway epithelia that 83 inactivate potential pathogens and modulate immune signaling (4, 5). The two gel-84 forming mucins in the lungs, MUC5B and MUC5AC, are encoded by adjacent genes on 85 chromosome 11p15.5 and are essential for lung health (4, 6, 7). Mice and humans with 86 genetic mutations lacking MUC5B develop severe pneumonia and upper airway 87 obstruction due to impaired mucociliary clearance, whereas overexpression leads to 88 pulmonary fibrosis (8-11). Similarly, MUC5AC is strongly induced by inflammation and 89 influences pathogen clearance, asthma pathogenesis, and may contribute to TB immune escape during helminthic co-infection by altering inflammatory responses (12-16). 90 91 Therefore, mucins may influence initial TB infection by altering mucociliary clearance and 92 initial infection of alveolar macrophages or TB dissemination by altering dynamics of 93 inflammation. However, the role of mucins in TB pathogenesis is unknown.

Multiple lines of evidence demonstrate that host genetics influence TB risk (17). Prior genetic association studies have generally focused on immune recognition and response mediators. Variation in Toll-like receptor (TLR) 2, TLR9, mannose binding protein (MBP), leukotriene A4 hydrolase (LTA4H), and toll interacting protein (TOLLIP),

98 have been associated with TBM susceptibility (18-22). Similarly, LTA4H and CD43 99 variants have been linked to higher risk of mortality from TBM (23, 24). However, the 100 influence of genetic polymorphisms in non-immune factors produced in the lung, such as 101 mucins, on immune function, TB susceptibility, or extrapulmonary spread are not known. 102 Genetic studies provide a powerful tool for examining how novel genes, such as 103 mucin genes, influence TB pathogenesis. Evaluation of immune phenotypes that 104 correlate with disease outcomes may detect novel variants associated with TB 105 susceptibility and mortality. Studies of genetically regulated cytokine responses in 106 Bacillus Calmette-Guerin (BCG)-specific T cells, dendritic cells, and peripheral blood 107 mononuclear cells (PBMCs) have identified potential TB susceptibility factors (21, 25-27). 108 Variants that influence functional responses in tissues of interest represent attractive 109 secondary traits that can be correlated with TB susceptibility, and these correlations may 110 provide insight into genetic mechanisms of disease susceptibility (25)(28). Because CSF 111 TNF concentrations have been linked with TBM outcomes and pathogenesis (23, 29), we 112 evaluated variants in the mucin gene region for association with TNF and other CSF 113 cytokines, followed by evaluation of candidate susceptibility SNPs with tuberculosis 114 outcomes, including pulmonary TB and TBM susceptibility, morbidity, and mortality.

- 115
- 116

117 METHODS

118 SNP selection

119 Genotyping and single nucleotide polymorphism (SNP) quality control (QC) are 120 described in the **Supplementary Methods**. SNPs within and around (± 10kb), the

MUC5B and *MUC5AC* gene region were identified using a haplotype-tagging approach from a genome-wide SNP dataset of TBM cases (N=407) and primary angle closure glaucoma (PACG) controls (N=1,139) (21, 30). Four SNPs were selected based on linkage disequilibrium (LD, $r^2 < 0.1$).

125 As a screening step, the four selected SNPs were evaluated for associations with 126 log₂ concentrations (pg/mL) of TNF in cerebral spinal fluid (CSF) collected at enrollment 127 from 154 participants in the discovery cohort (defined below). Cytokine concentrations 128 and CSF leukocytes were measured and compared using standard statistical methods 129 (see Supplementary Methods) (31). Only SNPs associated with significant changes in log₂ TNF CSF concentrations were carried forward in further analyses. The association 130 131 between SNPs of interest and CSF cytokine concentrations was confirmed using data 132 from validation cohort 2 (N=468, defined below) as described in the **Supplementary** Methods. 133

134

135 **Evaluation of TB Outcomes**

The association between SNPs of interest and TBM status was assessed between TBM cases (N=407) and PACG controls (N=1,1339) (21, 30) using logistic regression based on an additive genetic model (AA versus [vs] Aa vs aa), with adjustment for the first three principal components (PCs) using plink v1.9 (32). Analyses were repeated using cases of pulmonary TB as described in the **Supplementary Methods**.

141 The association between *MUC5AC* SNP rs28737416 and TBM morbidity and 142 mortality was analyzed in a discovery cohort consisting of participants enrolled in a study 143 of intensified therapy (including dexamethasone) in Vietnam (ISRCTN61649292) for

whom genotyping data were available (N=211, all HIV-1 seronegative) (33). The association between rs28737416 and time to death due to TBM (33) were evaluated using Kaplan-Meier estimates and compared by log-rank testing (survival package version 3.2-13, R version 4.0.2). Hazard ratios were calculated using the Cox proportional hazards model. Potential confounders, including i) weight; ii) duration of illness; iii) age; and iv) Glasgow coma score (GCS) were evaluated for associations with the outcomes of interest; those with a p-value ≤ 0.2 were used in adjusted analyses.

151 Survival analyses were repeated in two independent cohorts. The Vietnam 152 validation cohort included 87 participants enrolled in a randomized trial in Vietnam to 153 assess TBM survival with dexamethasone therapy (34). All participants with genotyping 154 data available were HIV-1 seronegative. For consistency with the Vietnam discovery 155 cohort, only participants who received dexamethasone were included. The Indonesia 156 validation cohort included 418 HIV-1 seronegative and 50 HIV-1 seropositive participants 157 enrolled in a prospective cohort study of TBM in Indonesia, all of whom received 158 dexamethasone (35, 36).

Information on censoring and missing data are in the Supplementary Methods.
All participants provided written, informed consent. Country and institution specific ethical
approvals were obtained as described (21, 30, 33-35).

162

163 Evaluation of expression quantitative trait loci (eQTLs)

164 The association between SNPs and mucin mRNA expression in lung tissue was 165 evaluated using the Genotype-Tissue Expression Project (GTEx) eQTL Calculator

166 (https://www.gtexportal.org/home/testyourown, accessed 07/27/2021; see

- 167 **Supplementary Methods**) (37).
- 168
- 169
- 170 **RESULTS**

A MUC5AC promoter region SNP is associated with lower concentrations of CSF TNF and IFNγ

A total of 126 SNPs were available in the TBM genome-wide SNP dataset within and around (± 10kb) the *MUC5B* and *MUC5AC* gene region. Three tagging SNPs were identified in *MUC5B*, and one tagging SNP was identified in the *MUC5AC* promoter region (**Figure 1A**). None of the *MUC5B* or *MUC5AC* SNPs were in high LD with one another (**Figure 1B**). *MUC5AC* SNP rs28737416 was not in LD with either of two *TOLLIP* gene SNPs (rs5743854 and rs3750920) previously linked to TBM susceptibility (**Table E1**) (21, 26).

180 Next, we analyzed the association between haplotype tagging SNPs and TNF 181 expression in CSF collected from participants enrolled in the Vietnam discovery cohort. 182 Using an allelic genetic model as our primary screening analysis, the major (C) allele in 183 MUC5AC SNP rs28737416 was associated with a median 2.7-fold log₂ higher concentration of CSF TNF compared to the minor (T) allele (p=7.2 *10⁻⁸; Figure 2A). No 184 185 other SNPs were associated with changes in CNS TNF cytokine concentrations. We 186 compared alternate genetic models (additive, AA versus [vs.] Aa vs. aa genotypes and 187 dominant, AA vs. Aa/aa genotypes) of inheritance to determine the best fitting model 188 (Figure 2B and 2C). The dominant model best fit this data, so we used this model for all

future genetic analyses. Using this approach, SNP rs28737416 T/T and T/C genotypes were significantly associated with lower CSF concentrations of TNF ($p=1.8*10^{-8}$) and IFN γ ($p=2.3*10^{-6}$), and higher CSF concentrations of IL-2 ($p=4.8*10^{-6}$) and IL-10 (p=0.0047) after application of a Bonferroni corrected (0.05/10 cytokines) p-value threshold of <0.005 (**Figure 2C**).

194 We performed PCA of cytokine concentrations to evaluate the relationship 195 between cytokines and reduce the number of statistical comparisons. We found two 196 uncorrelated factors, Factor 1 and Factor 2 (R^2 =0.08). Factor 1 had an eigenvalue of 5.46, 197 explaining 74.1% of the variability in the data. Factor 2 had an eigenvalue of 1.02, 198 explaining 13.8% variability in the data, and was influenced almost entirely by variability 199 in TNF (loading value=0.59) and IFN γ (loading value=0.57) (see **Supplementary** 200 Results). Factor 1 was not associated with the presence of the C/C genotype (exponentiated $[exp]\beta=0.88$, 95% CI 0.73, 1.06; p=0.19). However, Factor 2 was 201 associated with the C/C genotype (exp β =0.63, 95% CI 0.50, 0.79; p=4.9*10⁻⁵), suggesting 202 203 that variations in TNF and IFN γ concentrations are influenced by differences in genotype. 204 We validated the association of rs28737416 with TNF concentrations in the CSF 205 collected from participants in the Indonesia validation cohort. As in the Vietnam discovery 206 cohort, the T/T and T/C genotype of rs28737416 was associated with lower TNF concentrations (estimate [est] = -0.44, p=0.008) and IFN_{γ} (est = -0.67, p =0.03). The 207 208 relationship between expression of additional CSF cytokines and TBM in this cohort are 209 presented in Table E2. These data demonstrate the generalizability of this genetic 210 phenotype of TBM immune response across ethnically distinct populations.

211 Based on these preliminary observations, we evaluated the association between 212 the candidate SNP rs28737416 and total number of CSF white blood cells (exp β =1.23, 213 95% CI 0.90, 1.70; p=0.19), neutrophils (expβ=1.05, 95% CI 0.83, 1.34; p=0.68), and 214 lymphocytes (exp_β=1.25, 95% CI 0.90,1.74; p=0.18) in the Vietnam discovery cohort 215 using a dominant genotypic model. The exp β representing the mean change in cell 216 concentration between participants with a composite of the T/C and T/T genotypes 217 compared to participants with the C/C genotype. These data suggest that MUC5AC SNP 218 rs28737416 T allele is associated with lower CSF concentrations of TNF and IFN γ in 219 individuals with TBM, independent from total CSF cell count.

220

221 MUC5AC SNP rs28737416 is associated with TBM susceptibility and mortality

Because rs28737416 T allele was associated with lower TNF in individuals with TBM, we further analyzed the association between *MUC5AC* SNP rs28737416 and TBM susceptibility by case-control analysis (see methods). SNP rs28737416 was associated with susceptibility to TBM (OR=1.24, 95% CI 1.03, 1.49; p=0.02) (**Table 1**), but not pulmonary TB (OR=1.11, 95% CI 0.98, 1.25; p=0.10).

227 Selected genes may influence progression of disease above susceptibility (24), so 228 we next considered whether *MUC5AC* SNP rs28737416 was associated with TBM 229 mortality in the Vietnam discovery cohort and two independent validation cohorts. 230 Baseline characteristics for each cohort are shown in **Table 2**.

Survival analyses were first performed in the Vietnam discovery cohort with SNP rs28737416. We found a greater proportion of participants with T/T and T/C genotypes died (35/119, 30.4%) compared to those with the C/C genotype (11/89, 12.4%) (p=0.005)

(Figure 3A), which corresponded to a 61% lower risk of death among participants with
the C/C genotype (hazard ratio [HR] 0.39, 95% CI 0.20, 0.77; p=0.006). This association
persisted after adjustment for age and GCS (adjusted HR [aHR] 0.31, 95% CI 0.16, 0.63;
p=0.001). Adjustment for principal components representing genetic substructure did not
alter the results (data not shown). SNP rs2873716 T allele was associated with higher
risk mortality in an additive model as well (Figure E1).

Results were confirmed in a Vietnam validation cohort and a separate Indonesia validation cohort. In the Vietnam validation cohort, more T/T and T/C participants (9/47, 19.1%) died compared to those with the C/C genotype (1/40, 2.5%; p=0.02) (**Figure 4A**), representing an 87.1% lower risk of death from TBM (HR 0.13, 95% CI 0.02, 1.02, p=0.05). The association was similar after adjustment for age, weight, and GCS (aHR 0.13, 95% CI 0.02, 1.13; p=0.06).

246 We measured the association between rs28737416 and TBM mortality in the 247 Indonesia validation cohort, which included both HIV-1 seronegative (N=418) and 248 seropositive (N=50) participants. A higher number of participants with the rs28737416 T/T 249 and T/C genotypes died (127/287, 44.3%) compared to those with the C/C genotype 250 (65/181, 35.9%, p=0.06) (Figure 4B), corresponding to a 20.1% lower risk of death 251 among participants with the C/C genotype (HR 0.80, 95% CI 0.66, 0.99; p=0.04). 252 However, this association was attenuated after adjustment for age and GCS (aHR=0.87, 253 95% CI 0.69, 1.09 p=0.22). In sensitivity analyses using only HIV seronegative 254 participants, more participants with the T/T and T/C genotypes (106/252, 42.1%) died 255 compared to those with the C/C genotype (56/166, 33.7%, p=0.08). The resultant risk of 256 death was 24.8% lower among participants with the C/C genotype, and of borderline

statistical significance (HR=0.75, 95% CI 0.54, 1.04; p=0.08) (Figure E2). Data on the
 proportional hazards assumptions for both the discovery and validation cohorts is
 included in the Supplementary Results. Taken together, these data suggest that
 MUC5AC SNP rs28737416 is associated with TBM susceptibility and mortality.

261 SNP rs28737416 is associated with mRNA expression of MUC5AC but not MUC5B

- 262 To explore potential mechanisms for the association between mucins and TBM 263 mortality, the association between rs28737416 and MUC5B / MUCAC mRNA expression 264 in healthy lung tissues was assessed using public datasets (37). Participants with the T/T 265 (0.11) genotype had significantly higher median normalized MUC5AC mRNA expression 266 compared to those with the T/C (0.06) or C/C (-0.05) genotype (normalized effect size 267 [NES] -0.14, p=0.009). There was no association between rs28737416 and MUC5B 268 expression in lung tissues (NES= -0.021, p=0.67). Thus, the rs28737416 T allele is 269 associated with higher basal MUC5AC expression in lung tissue, lower CSF expression 270 of TNF and IFN γ , and higher risk of TBM mortality.
- 271

272 **DISCUSSION**

This is the first study to link polymorphisms in a mucin gene with tuberculosis disease. Specifically, SNP rs28737416 T allele was associated with higher expression of *MUC5AC* in lung tissues, lower CSF concentrations of TNF and IFN γ in participants with TBM, and higher susceptibility and risk of death from TBM. These findings suggest that the mucosal barrier plays an important role in *Mycobacterium tuberculosis* pathogenesis.

279 Common variants in MUC5AC are associated with lung diseases, including 280 COVID-19, and asthma (38-40). Each of these variants are in strong LD with our variant 281 of interest in the Vietnamese population, suggesting that functional variation in MUC5AC 282 may influence disease outcomes. In this study, genetic variation associated with 283 diminished MUC5AC expression in the lungs of healthy individuals was protective from 284 development of TBM. MUC5AC is induced during inflammation and protects against viral 285 infection (4, 14, 15). However, over-expression of MUC5AC is associated with severe 286 asthma exacerbation and ventilator-associated lung injury (13, 41). Thus, our findings fit 287 a model where MUC5AC contributes to the pathogenesis of respiratory inflammation and 288 infection.

289 How MUC5AC contributes to TBM mortality is unclear. It is unlikely that MUC5AC 290 directly influences meningeal inflammation, as MUC5AC is not expressed in the central 291 nervous system or within *M. tuberculosis*-infected myeloid cells (42). One possible 292 explanation for the findings presented here is that over-expression of MUC5AC facilitates 293 breakdown of the mucosal barrier, alveolar passage through the respiratory epithelium, 294 and dissemination of *M. tuberculosis*. A similar mechanism of action has been proposed 295 for the complement protein mannose binding protein (MBP), which may promote 296 dissemination to the brain at higher concentrations (22, 43). Furthermore, MUC5AC may 297 influence systemic immune responses, leading to altered *M. tuberculosis* pathogenesis. 298 For example, MUC5AC variants are associated with total peripheral eosinophil count, 299 suggesting that *MUC5AC* may play a role in conditioning systemic immune responses 300 (38, 44). In this study, TNF and IFN γ concentrations were lower in the CSF of participants 301 with the susceptible phenotype, while IL-2 concentrations were higher. These findings are

302 consistent with other studies demonstrating that lower concentrations of CSF TNF and 303 IFN γ are associated with TBM mortality among persons who receive dexamethasone 304 therapy (23).

305 Based on the pattern of cytokines influenced rs28737416, MUC5AC may be 306 important for the development of effective T cell responses during *M. tuberculosis* 307 infection. Protective T cell responses against *M. tuberculosis* are generated when *M.* 308 tuberculosis antigens are trafficked by dendritic cells from the lung to draining lymph 309 nodes (LN), leading to T cell activation and differentiation (45, 46). Polymorphisms in 310 *MUC5AC* may delay DC migration to the LN, which impairs immunity to *M. tuberculosis* 311 in mice (46). Further study using methods to measure macrophage and T cell responses 312 in the presence of MUC5AC polymorphisms will be required to better understand how 313 *MUC5AC* influences TBM pathogenesis.

314 This study should be interpreted in the context of several limitations. First, it is 315 possible that the susceptibility findings from the case-control analysis were detected due 316 to another SNP (eQTL) being responsible for the change in MUC5AC expression. 317 However, this appears unlikely, as rs28737416 was only associated with MUC5AC. 318 Second, there is a potential for confounding due to population structure in the highly 319 homogenous Vietnamese population. To address this potential limitation, adjustment for 320 principal components representative of genetic substructure was performed and did not 321 significantly alter the results. Additionally, the findings were confirmed in a separate 322 cohort of participants in Indonesia, further suggesting genetic substructure was not 323 influencing these results. The association in the Indonesia validation cohort was not as 324 strong as in the Vietnamese cohorts, although the similarity in the trend in an ethnically

325 distinct cohort provides additional evidence for an association between MUC5AC and 326 TBM. The reason for this discrepancy may be due to differences in i) illness severity or 327 time to clinical presentation across cohorts; ii) sample-sizes between cohorts; iii), linkage 328 disequilibrium patterns across ethnicity; or, iv) environmental influence. Nonetheless, 329 these data provide some of the strongest genetic association between a polymorphism 330 and TBM currently. Future studies in additional cohorts and ongoing fine mapping studies 331 may provide further insights into this modest discrepancy (23, 47, 48). Third, some 332 participants may have been misclassified at enrollment with TBM. However, classification 333 of TBM was performed using pre-specified criteria, which generally results in random 334 misclassification (e.g., non-differential misclassification) and would bias away from finding 335 an association. Fourth, although we found an association between rs28737416 and lung 336 expression, MUC5AC is also expressed in the gastrointestinal tract. It is possible that 337 TBM susceptibility is modified by changes in gut microbiota that are influenced by 338 *MUC5AC* (47). Thus, these findings provide intriguing data for future mechanistic study. 339 In summary, polymorphisms in MUC5AC are associated with higher lung MUC5AC 340 mRNA expression, lower TNF and IFN γ in the CSF, and higher risk of mortality due to 341 TBM. These data provide evidence that respiratory mucins play an important role in TBM 342 pathogenesis.

344 **ACKNOWLEDGEMENTS**

345	We would like to thank all the participants in the parent studies used in these
346	analyses. We would also like to acknowledge the clinical, laboratory and administrative
347	staff at each study site for their dedication and assistance with this project. Finally, we
348	would like to acknowledge the GTEx Project, which supports the platform on which eQTL
349	analyses were performed. At the time of publication, the GTEx Project was supported by
350	the Common Fund of the Office of the Director of the National Institutes of Health, and by
351	NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described
352	in this manuscript were obtained from the GTEx Portal eQTL calculator on 07/28/2021.
353	

355 **REFERENCES**

- 356 1. Furin J, Cox H, Pai M. Tuberculosis. *Lancet* 2019; 393: 1642-1656.
- 2. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan
- 358 S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. *Nat Rev Dis*
- 359 *Primers* 2016; 2: 16076.
- 360 3. Stadelman AM, Ellis J, Samuels THA, Mutengesa E, Dobbin J, Ssebambulidde K,
- 361 Rutakingirwa MK, Tugume L, Boulware DR, Grint D, Cresswell FV. Treatment Outcomes
- 362 in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis. *Open Forum*
- 363 Infect Dis 2020; 7: ofaa257.
- 4. Lillehoj EP, Kato K, Lu W, Kim KC. Cellular and molecular biology of airway mucins. *Int Rev Cell Mol Biol* 2013; 303: 139-202.
- 366 5. McShane A, Bath J, Jaramillo AM, Ridley C, Walsh AA, Evans CM, Thornton DJ, Ribbeck K.
 367 Mucus. *Curr Biol* 2021; 31: R938-R945.
- 368 6. Nucleotide [Internet]. Bethesda (MD): National Library of Medicine (US) NCfBIANN, Homo
- 369 sapiens mucin 5AC, oligomeric mucus/gel-forming (MUC5AC), mRNA; [cited
- 370 2021/09/20]. Available from: https://www.ncbi.nlm.nih.gov/nuccore/NM_001304359.2.
- 371 7. Nucleotide [Internet]. Bethesda (MD): National Library of Medicine (US) NCfBIANN, Homo
- 372 sapiens mucin 5B, oligomeric mucus/gel-forming (MUC5B), mRNA; [cited 2021/09/20].
 373 Available from: https://www.ncbi.nlm.nih.gov/nuccore/NM 002458.3.
- 8. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W,
- 375 Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, du
- Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer
- 377 SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA. A common
- 378 MUC5B promoter polymorphism and pulmonary fibrosis. *N Engl J Med* 2011; 364: 1503-
- **379 1512**.

380	9. Hancock LA, Hennessy CE, Solomon GM, Dobrinskikh E, Estrella A, Hara N, Hill DB, Kissner
381	WJ, Markovetz MR, Grove Villalon DE, Voss ME, Tearney GJ, Carroll KS, Shi Y,
382	Schwarz MI, Thelin WR, Rowe SM, Yang IV, Evans CM, Schwartz DA. Muc5b
383	overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice. Nat
384	<i>Commun</i> 2018; 9: 5363.
385	10. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander
386	SN, Bellinghausen LK, Song AS, Petrova YM, Tuvim MJ, Adachi R, Romo I, Bordt AS,
387	Bowden MG, Sisson JH, Woodruff PG, Thornton DJ, Rousseau K, De la Garza MM,
388	Moghaddam SJ, Karmouty-Quintana H, Blackburn MR, Drouin SM, Davis CW, Terrell
389	KA, Grubb BR, O'Neal WK, Flores SC, Cota-Gomez A, Lozupone CA, Donnelly JM,
390	Watson AM, Hennessy CE, Keith RC, Yang IV, Barthel L, Henson PM, Janssen WJ,
391	Schwartz DA, Boucher RC, Dickey BF, Evans CM. Muc5b is required for airway
392	defence. Nature 2014; 505: 412-416.
393	11. Costain G, Liu Z, Mennella V, Radicioni G, Goczi AN, Albulescu A, Walker S, Ngan B,
394	Manson D, Vali R, Khan M, Palaniyar N, Hill DB, Hall DA, Marshall CR, Knowles M,
395	Zariwala MA, Kesimer M, Dell SD. Hereditary Mucin Deficiency Caused by Biallelic Loss
396	of Function of MUC5B. Am J Respir Crit Care Med 2022; 205: 761-768.
397	12. Monin L, Griffiths KL, Lam WY, Gopal R, Kang DD, Ahmed M, Rajamanickam A, Cruz-
398	Lagunas A, Zuniga J, Babu S, Kolls JK, Mitreva M, Rosa BA, Ramos-Payan R, Morrison
399	TE, Murray PJ, Rangel-Moreno J, Pearce EJ, Khader SA. Helminth-induced arginase-1
400	exacerbates lung inflammation and disease severity in tuberculosis. J Clin Invest 2015;
401	125: 4699-4713.
402	13. Altman MC, Flynn K, Rosasco MG, Dapas M, Kattan M, Lovinsky-Desir S, O'Connor GT, Gill
403	MA, Gruchalla RS, Liu AH, Pongracic JA, Khurana Hershey GK, Zoratti EM, Teach SJ,
404	Rastrogi D, Wood RA, Bacharier LB, LeBeau P, Gergen PJ, Togias A, Busse WW,
405	Presnell S, Gern JE, Ober C, Jackson DJ, Consortium NICA. Inducible expression

- quantitative trait locus analysis of the MUC5AC gene in asthma in urban populations of
 children. *J Allergy Clin Immunol* 2021.
- 408 14. Cho HY, Park S, Miller L, Lee HC, Langenbach R, Kleeberger SR. Role for Mucin-5AC in
- 409 Upper and Lower Airway Pathogenesis in Mice. *Toxicol Pathol* 2021; 49: 1077-1099.
- 410 15. Ehre C, Worthington EN, Liesman RM, Grubb BR, Barbier D, O'Neal WK, Sallenave JM,
- 411 Pickles RJ, Boucher RC. Overexpressing mouse model demonstrates the protective role

412 of Muc5ac in the lungs. *Proc Natl Acad Sci U S A* 2012; 109: 16528-16533.

- 413 16. Hasnain SZ, Evans CM, Roy M, Gallagher AL, Kindrachuk KN, Barron L, Dickey BF, Wilson
- 414 MS, Wynn TA, Grencis RK, Thornton DJ. Muc5ac: a critical component mediating the

415 rejection of enteric nematodes. *J Exp Med* 2011; 208: 893-900.

- 416 17. Correa-Macedo W, Cambri G, Schurr E. The Interplay of Human and Mycobacterium
 417 Tuberculosis Genomic Variability. *Front Genet* 2019; 10: 865.
- 418 18. Thuong NT, Hawn TR, Thwaites GE, Chau TT, Lan NT, Quy HT, Hieu NT, Aderem A, Hien
- 419 TT, Farrar JJ, Dunstan SJ. A polymorphism in human TLR2 is associated with increased 420 susceptibility to tuberculous meningitis. *Genes Immun* 2007; 8: 422-428.

421 19. Tobin DM, Vary JC, Jr., Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge S,

- 422 King MC, Hawn TR, Moens CB, Ramakrishnan L. The Ita4h locus modulates
- 423 susceptibility to mycobacterial infection in zebrafish and humans. *Cell* 2010; 140: 717-
- 424 730.

425 20. Graustein AD, Horne DJ, Arentz M, Bang ND, Chau TT, Thwaites GE, Caws M, Thuong NT,

- 426 Dunstan SJ, Hawn TR. TLR9 gene region polymorphisms and susceptibility to
- 427 tuberculosis in Vietnam. *Tuberculosis (Edinb)* 2015; 95: 190-196.
- 428 21. Shah JA, Vary JC, Chau TT, Bang ND, Yen NT, Farrar JJ, Dunstan SJ, Hawn TR. Human
- 429 TOLLIP Regulates TLR2 and TLR4 Signaling and Its Polymorphisms Are Associated
- 430 with Susceptibility to Tuberculosis. *J Immunol* 2012; 189: 1737-1746.

431	22. Hoal-Van Helden EG, Epstein J, Victor TC, Hon D, Lewis LA, Beyers N, Zurakowski D,
432	Ezekowitz AB, Van Helden PD. Mannose-binding protein B allele confers protection
433	against tuberculous meningitis. Pediatr Res 1999; 45: 459-464.
434	23. Thuong NTT, Heemskerk D, Tram TTB, Thao LTP, Ramakrishnan L, Ha VTN, Bang ND,
435	Chau TTH, Lan NH, Caws M, Dunstan SJ, Chau NVV, Wolbers M, Mai NTH, Thwaites
436	GE. Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral
437	Inflammation and Survival From Tuberculous Meningitis. J Infect Dis 2017; 215: 1020-
438	1028.
439	24. Campo M, Randhawa AK, Dunstan S, Farrar J, Caws M, Bang ND, Lan NN, Hong Chau TT,
440	Horne DJ, Thuong NT, Thwaites GE, Hawn TR. Common polymorphisms in the CD43
441	gene region are associated with tuberculosis disease and mortality. Am J Respir Cell
442	Mol Biol 2015; 52: 342-348.
443	25. Venkatasubramanian S, Pryor R, Plumlee C, Cohen SB, Simmons JD, Warr AJ, Graustein
444	AD, Saha A, Hawn TR, Urdahl KB, Shah JA. TOLLIP Optimizes Dendritic Cell
445	Maturation to Lipopolysaccharide and Mycobacterium tuberculosis. J Immunol Baltim Md
446	1950 2022.
447	26. Shah JA, Musvosvi M, Shey M, Horne DJ, Wells RD, Peterson GJ, Cox JS, Daya M, Hoal
448	EG, Lin L, Gottardo R, Hanekom WA, Scriba TJ, Hatherill M, Hawn TR. A Functional
449	Toll-Interacting Protein Variant Is Associated with Bacillus Calmette-Guerin-Specific
450	Immune Responses and Tuberculosis. Am J Respir Crit Care Med 2017; 196: 502-511.
451	27. Li Y, Oosting M, Deelen P, Ricano-Ponce I, Smeekens S, Jaeger M, Matzaraki V, Swertz
452	MA, Xavier RJ, Franke L, Wijmenga C, Joosten LA, Kumar V, Netea MG. Inter-individual
453	variability and genetic influences on cytokine responses to bacteria and fungi. Nat Med
454	2016; 22: 952-960.
455	28. Shah JA, Warr AJ, Graustein AD, Saha A, Dunstan SJ, Thuong NTT, Thwaites GE, Caws
456	M, Thai PVK, Bang ND, Chau TTH, Khor CC, Li Z, Hibberd M, Chang X, Nguyen FK,

457	Hernandez CA, Jones MA, Sassetti CM, Fitzgerald KA, Musvosvi M, Gela A, Hanekom
458	WA, Hatherill M, Scriba TJ, Hawn TR. REL and BHLHE40 Variants Are Associated with
459	IL-12 and IL-10 Responses and Tuberculosis Risk. The Journal of Immunology 2022:
460	ji2100671.
461	29. Whitworth LJ, Troll R, Pagan AJ, Roca FJ, Edelstein PH, Troll M, Tobin DM, Phu NH, Bang
462	ND, Thwaites GE, Thuong NTT, Sewell RF, Ramakrishnan L. Elevated cerebrospinal
463	fluid cytokine levels in tuberculous meningitis predict survival in response to
464	dexamethasone. Proc Natl Acad Sci U S A 2021; 118.
465	30. Khor CC, Do T, Jia H, Nakano M, George R, Abu-Amero K, Duvesh R, Chen LJ, Li Z,
466	Nongpiur ME, Perera SA, Qiao C, Wong HT, Sakai H, Barbosa de Melo M, Lee MC,
467	Chan AS, Azhany Y, Dao TL, Ikeda Y, Perez-Grossmann RA, Zarnowski T, Day AC,
468	Jonas JB, Tam PO, Tran TA, Ayub H, Akhtar F, Micheal S, Chew PT, Aljasim LA, Dada
469	T, Luu TT, Awadalla MS, Kitnarong N, Wanichwecharungruang B, Aung YY, Mohamed-
470	Noor J, Vijayan S, Sarangapani S, Husain R, Jap A, Baskaran M, Goh D, Su DH, Wang
471	H, Yong VK, Yip LW, Trinh TB, Makornwattana M, Nguyen TT, Leuenberger EU, Park
472	KH, Wiyogo WA, Kumar RS, Tello C, Kurimoto Y, Thapa SS, Pathanapitoon K, Salmon
473	JF, Sohn YH, Fea A, Ozaki M, Lai JS, Tantisevi V, Khaing CC, Mizoguchi T, Nakano S,
474	Kim CY, Tang G, Fan S, Wu R, Meng H, Nguyen TT, Tran TD, Ueno M, Martinez JM,
475	Ramli N, Aung YM, Reyes RD, Vernon SA, Fang SK, Xie Z, Chen XY, Foo JN, Sim KS,
476	Wong TT, Quek DT, Venkatesh R, Kavitha S, Krishnadas SR, Soumittra N, Shantha B,
477	Lim BA, Ogle J, de Vasconcellos JP, Costa VP, Abe RY, de Souza BB, Sng CC, Aquino
478	MC, Kosior-Jarecka E, Fong GB, Tamanaja VC, Fujita R, Jiang Y, Waseem N, Low S,
479	Pham HN, Al-Shahwan S, Craven ER, Khan MI, Dada R, Mohanty K, Faiq MA, Hewitt
480	AW, Burdon KP, Gan EH, Prutthipongsit A, Patthanathamrongkasem T, Catacutan MA,
481	Felarca IR, Liao CS, Rusmayani E, Istiantoro VW, Consolandi G, Pignata G, Lavia C,
482	Rojanapongpun P, Mangkornkanokpong L, Chansangpetch S, Chan JC, Choy BN,

483	Shum JW, Than HM, Oo KT, Han AT, Yong VH, Ng XY, Goh SR, Chong YF, Hibberd
484	ML, Seielstad M, Png E, Dunstan SJ, Chau NV, Bei J, Zeng YX, Karkey A, Basnyat B,
485	Pasutto F, Paoli D, Frezzotti P, Wang JJ, Mitchell P, Fingert JH, Allingham RR, Hauser
486	MA, Lim ST, Chew SH, Ebstein RP, Sakuntabhai A, Park KH, Ahn J, Boland G, Snippe
487	H, Stead R, Quino R, Zaw SN, Lukasik U, Shetty R, Zahari M, Bae HW, Oo NL, Kubota
488	T, Manassakorn A, Ho WL, Dallorto L, Hwang YH, Kiire CA, Kuroda M, Djamal ZE,
489	Peregrino JI, Ghosh A, Jeoung JW, Hoan TS, Srisamran N, Sandragasu T, Set SH,
490	Doan VH, Bhattacharya SS, Ho CL, Tan DT, Sihota R, Loon SC, Mori K, Kinoshita S,
491	Hollander AI, Qamar R, Wang YX, Teo YY, Tai ES, Hartleben-Matkin C, Lozano-Giral D,
492	Saw SM, Cheng CY, Zenteno JC, Pang CP, Bui HT, Hee O, Craig JE, Edward DP,
493	Yonahara M, Neto JM, Guevara-Fujita ML, Xu L, Ritch R, Liza-Sharmini AT, Wong TY,
494	Al-Obeidan S, Do NH, Sundaresan P, Tham CC, Foster PJ, Vijaya L, Tashiro K, Vithana
495	EN, Wang N, Aung T. Genome-wide association study identifies five new susceptibility
496	loci for primary angle closure glaucoma. Nat Genet 2016; 48: 556-562.
497	31. Beardsley J, Hoang NLT, Kibengo FM, Tung NLN, Binh TQ, Hung LQ, Chierakul W,
498	Thwaites GE, Chau NVV, Nguyen TTT, Geskus RB, Day JN. Do Intracerebral Cytokine
499	Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency
500	Virus-associated Cryptococcal Meningitis? Clin Infect Dis 2019; 68: 1494-1501.
501	32. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de
502	Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and
503	population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
504	33. Heemskerk AD, Bang ND, Mai NT, Chau TT, Phu NH, Loc PP, Chau NV, Hien TT, Dung
505	NH, Lan NT, Lan NH, Lan NN, Phong le T, Vien NN, Hien NQ, Yen NT, Ha DT, Day JN,
506	Caws M, Merson L, Thinh TT, Wolbers M, Thwaites GE, Farrar JJ. Intensified
507	Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med 2016;
508	374: 124-134.

509 34. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH,

- 510 Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran
- 511 TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ.
- 512 Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. *N*
- 513 Engl J Med 2004; 351: 1741-1751.
- 514 35. van Laarhoven A, Dian S, Ruesen C, Hayati E, Damen M, Annisa J, Chaidir L, Ruslami R,
- 515 Achmad TH, Netea MG, Alisjahbana B, Rizal Ganiem A, van Crevel R. Clinical
- 516 Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of
- 517 Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia. J Infect Dis
- 518 2017; 215: 1029-1039.
- 519 36. van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricano-Ponce I, Ruesen C,
- 520 Annisa J, Koeken V, Chaidir L, Li Y, Achmad TH, Joosten LAB, Notebaart RA, Ruslami
- 521 R, Netea MG, Verbeek MM, Alisjahbana B, Kumar V, Clish CB, Ganiem AR, van Crevel
- 522 R. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an
- 523 observational cohort study. *Lancet Infect Dis* 2018; 18: 526-535.
- 524 37. Poral TG. Analysis Methods. 08/20/2019 07/30/2021]. Available from:
- 525 <u>https://www.gtexportal.org/home/documentationPage#staticTextAnalysisMethods</u>.
- 526 38. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A,
- 527 Morales J, Mountjoy E, Sollis E, Suveges D, Vrousgou O, Whetzel PL, Amode R, Guillen
- 528 JA, Riat HS, Trevanion SJ, Hall P, Junkins H, Flicek P, Burdett T, Hindorff LA,
- 529 Cunningham F, Parkinson H. The NHGRI-EBI GWAS Catalog of published genome-
- 530 wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids*
- 531 *Res* 2019; 47: D1005-D1012.
- 532 39. Shelton JF, Shastri AJ, Ye C, Weldon CH, Filshtein-Sonmez T, Coker D, Symons A,
- 533 Esparza-Gordillo J, and Me C-T, Aslibekyan S, Auton A. Trans-ancestry analysis reveals

534	genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat
535	Genet 2021; 53: 801-808.

- 40. Han Y, Jia Q, Jahani PS, Hurrell BP, Pan C, Huang P, Gukasyan J, Woodward NC, Eskin E,
- 537 Gilliland FD, Akbari O, Hartiala JA, Allayee H. Genome-wide analysis highlights
- 538 contribution of immune system pathways to the genetic architecture of asthma. *Nat*
- 539 *Commun* 2020; 11: 1776.
- 540 41. Koeppen M, McNamee EN, Brodsky KS, Aherne CM, Faigle M, Downey GP, Colgan SP,
- 541 Evans CM, Schwartz DA, Eltzschig HK. Detrimental role of the airway mucin Muc5ac
- 542 during ventilator-induced lung injury. *Mucosal Immunol* 2013; 6: 762-775.
- 543 42. MUC5AC. The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000215182-
- 544 <u>MUC5AC</u>; Accessed 12-13-2021.
- 545 43. Davis A, Meintjes G, Wilkinson RJ. Treatment of Tuberculous Meningitis and Its
 546 Complications in Adults. *Curr Treat Options Neurol* 2018; 20: 5.
- 547 44. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM,
- 548 Tardaguila M, Huffman JE, Ritchie SC, Megy K, Ponstingl H, Penkett CJ, Albers PK,
- 549 Wigdor EM, Sakaue S, Moscati A, Manansala R, Lo KS, Qian H, Akiyama M, Bartz TM,
- 550 Ben-Shlomo Y, Beswick A, Bork-Jensen J, Bottinger EP, Brody JA, van Rooij FJA,
- 551 Chitrala KN, Wilson PWF, Choquet H, Danesh J, Di Angelantonio E, Dimou N, Ding J,
- 552 Elliott P, Esko T, Evans MK, Felix SB, Floyd JS, Broer L, Grarup N, Guo MH, Guo Q,
- 553 Greinacher A, Haessler J, Hansen T, Howson JMM, Huang W, Jorgenson E, Kacprowski
- 554 T, Kahonen M, Kamatani Y, Kanai M, Karthikeyan S, Koskeridis F, Lange LA, Lehtimaki
- 555 T, Linneberg A, Liu Y, Lyytikainen LP, Manichaikul A, Matsuda K, Mohlke KL, Mononen
- 556 N, Murakami Y, Nadkarni GN, Nikus K, Pankratz N, Pedersen O, Preuss M, Psaty BM,
- 557 Raitakari OT, Rich SS, Rodriguez BAT, Rosen JD, Rotter JI, Schubert P, Spracklen CN,
- 558 Surendran P, Tang H, Tardif JC, Ghanbari M, Volker U, Volzke H, Watkins NA, Weiss S,
- 559 Program VAMV, Cai N, Kundu K, Watt SB, Walter K, Zonderman AB, Cho K, Li Y, Loos

560	RJF, Knight JC, Georges M, Stegle O, Evangelou E, Okada Y, Roberts DJ, Inouye M,
561	Johnson AD, Auer PL, Astle WJ, Reiner AP, Butterworth AS, Ouwehand WH, Lettre G,
562	Sankaran VG, Soranzo N. The Polygenic and Monogenic Basis of Blood Traits and
563	Diseases. Cell 2020; 182: 1214-1231 e1211.
564	45. Cohen SB, Gern BH, Delahaye JL, Adams KN, Plumlee CR, Winkler JK, Sherman DR,
565	Gerner MY, Urdahl KB. Alveolar Macrophages Provide an Early Mycobacterium
566	tuberculosis Niche and Initiate Dissemination. Cell Host Microbe 2018; 24: 439-446
567	e434.
568	46. Griffiths KL, Ahmed M, Das S, Gopal R, Horne W, Connell TD, Moynihan KD, Kolls JK,
569	Irvine DJ, Artyomov MN, Rangel-Moreno J, Khader SA. Targeting dendritic cells to
570	accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. Nat
571	<i>Commun</i> 2016; 7: 13894.
572	47. Dumas A, Corral D, Colom A, Levillain F, Peixoto A, Hudrisier D, Poquet Y, Neyrolles O.
573	The Host Microbiota Contributes to Early Protection Against Lung Colonization by
574	Mycobacterium tuberculosis. Front Immunol 2018; 9: 2656.
575	48. Fava VM, Schurr E. Evaluating the Impact of LTA4H Genotype and Immune Status on
576	Survival From Tuberculous Meningitis. J Infect Dis 2017; 215: 1011-1013.
577	
578	

Table 1: Association of *MUC5AC* SNP rs28737416 with diagnosis of TB meningitis and pulmonary TB

	TB Meningitis			
Genotype	Controls [⁺] (N = 1,139)	Cases (N = 407)	OR (95% CI)	P-value
C/C	582 (51.3%)	182 (45.4%)		
T/C	464 (40.9%)	169 (42.1%)	1.24 (1.03, 1.49)	0.021
T/T	89 (7.8%)	50 (12.5%)		
Pulmonary TB [*]				
	Controls [↑] (N = 1,270)	Cases (N = 1,380)		
C/C	655 (51.6%)	662 (48.0%)		
T/C	510 (40.2%)	588 (42.6%)	1.11 (0.98, 1.25)	0.100
T/T	100 (7.9%)	129 (9.3%)		

The association between diagnosis of TB meningitis or pulmonary TB (analyzed separately) and *MUC5AC* SNP rs28737416 was compared between cases and controls as described in the methods. The total number of individuals with major homozygous (C/C), heterozygous (T/C) and minor homozygous (T/T) genotypes are shown.

* Genotype data were missing for 5 cases and 1 control.

[†] Controls were generated from the same cohort of participants with primary angle closure glaucoma.

Abbreviations: TB, tuberculosis; SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval.

Table 2: Baseline characteristics

		Vietnam validation	Indonesia validation
General characteristics	Discovery Cohort N=211	N=87	cohort (N=468)
Age	43 (28, 57)	41 (25, 57)*	28 (22-37) [†]
Male sex	131 (62.1%)	37 (46.8%)*	230 (55%)
Weight (kilograms)	49 (45, 55)	45 (40, 49)	N/A [‡]
Disease Characteristics			
Duration of illness prior to presentation (days)	14 (10, 30)	17 (12, 30)*	N/A^{\ddagger}
CSF WBC count (leukocytes/mm ³)	81 (28, 231) [§]	209 (82, 375)	155 (53-336)
Glasgow coma score	15 (13, 15)	14 (13, 15)	13 (12-15) [†]
HIV seropositive	0 (0%)	0 (0%)	50 (10.7%)
Diagnostic category ^{II}			
Definite TBM	77 (36.5%)	51 (58.6%)	272 (65.1%)
Probable TBM	66 (31.3%)	27 (31.0%)	146 (34.9%
Possible TBM	68 (32.2%)	9 (10.3%)	-

Results are presented as median (interquartile range) for continuous variables or number (%) for categorical variables.

Abbreviations: CSF, cerebral spinal fluid; WBC, white blood cell count; TBM, tuberculosis meningitis.

* N=79 due to missingness.

[†] N=412 due to missingness.

[‡] Data not available.

[§] N=204 due to missingness.

^{II} Participant diagnostic category at study end. Diagnostic categories were defined according to consensus criteria or

study-specific criteria as described in the supplementary methods. Possible TBM was not defined in the Indonesia cohort.

Figure 1: Chromosome map and linkage disequilibrium plots of haplotype-

tagging SNPs identified in MUC5B and MUC5AC gene regions.

A. *MUC5B* and *MUC5AC* genes and SNPs of interest are located on band 1 of the p arm of chromosome 11 as shown. Vertical lines represent sub-band intervals of 0.004. **B.** Linkage disequilibrium plots showing R² (left) and D' (right) values for tagging SNPs. The degree of shading is proportionate to the R² and D' values for paired SNPs. **C.** Table listing the minor allele frequency (MAF) for each SNP.

Figure 2: Evaluation of CSF cytokine expression in TBM patients with *MUC5B* and *MUC5AC* SNPs assessed by allelic, additive, and dominant genetic models.

(A) Log₂ TNF concentrations (pg/mL) measured in CSF were compared using Wilcoxon rank sum for tagging SNPs based on an allelic model (e.g., comparison of total number of alleles). For each SNP, the major allele is represented by black circles, and the minor allele is indicated by grey circles. Measured cytokine concentrations were counted twice, as all participants contribute two alleles. The association between *MUC5AC* SNP rs28737416 and additional log₂ CSF cytokine concentrations (pg/mL) were evaluated using additive (**B**) and dominant genetic models (**C**). For the additive model, cytokine concentrations were compared between those with the T/T (grey circles), T/C (open circles), or C/C (black circles) genotypes using the Kruskal-Wallis test. In the dominant model, the composite of the T/T and T/C genotypes (grey circles) were compared to the C/C genotype (black circles) using Wilcoxon rank-sum testing. For all graphs, the median is indicated by a thick, horizontal red line, and the interquartile range is represented by thin, horizontal red lines. To adjust for multiple comparisons, a Bonferroni correction was

applied to the results in B and C, and significance threshold adjusted to the level of p <0.005. P-values for cytokines with statistically significant differences in expression after Bonferroni correction are shown.

Figure 3: Kaplan Meier curves comparing survival in a dominant allelic model of *MUC5AC* SNP rs28737416 in the discovery cohort.

Kaplan-Meier curves displaying time to death using a dominant allelic model comparing participants with the T/T and T/C genotypes to those with the C/C genotype are shown. Displayed p-values represent comparison of the survival distributions by the log-rank test.

Figure 4: Kaplan Meier curves comparing survival in a dominant allelic model of *MUC5AC* SNP rs28737416 in the validation cohorts.

Kaplan-Meier curves displaying time to death using a dominant allelic model comparing participants with T/T and T/C genotypes to those with the C/C genotype in the Vietnam validation cohort (**A**) and the Indonesia validation cohort (**B**) are shown. Displayed p-values represent comparison of the survival distributions by the log-rank test.



rs7946008

rs6578810

1.00

0.46

rs2037089

1.00

rs7946008

rs6578810

0.26

0.21

rs28737416

rs7946008

rs6578810

0.00

0.03

rs28737416

0.00

0.00

rs2037089

0.01

rs7946008

rs6578810

rs7946008

rs6578810

0.03

0.40









Β.

